Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 12;13:77. doi: 10.1186/s13148-021-01052-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 2 — EZH2 mutations result in decreased EZH2 protein expression. a Representative examples of EZH2 immunolabeling of control and four patient BM biopsies. Immunolabeling of normal BM biopsies shows on average a moderate nuclear expression level score of 2 in hematopoietic cells (samples 1, 2) while a reactive nodular lymphoid infiltrate in (1) is completely negative. BM samples of two EZH2-wt patients show strong (sample 3, IHC score 3) or moderate (sample 4, score 2) EZH2 expression. In contrast, EZH2 staining intensity is negative (sample 5, score 0) or weakly positive (sample 6, score 1) in BM biopsies of two EZH2-mut patients. Samples 3 and 5 are derived from patients with intact chromosome 7, samples 4 and 6 from patients with del(7q)/-7. b Median and range of EZH2 protein expression by IHC depending on EZH2 mutation and chromosome 7 status. EZH2 expression is lower (p = 0.0002 by two-way ANOVA) in patients with an EZH2 mutation compared to patients with wild-type EZH2. The reduction is similar in patients with and without chromosome 7q losses or deletions, but patients with del(7q)/-7 tended to have lower EZH2 expression levels than patients with intact chromosome 7 (p = 0.07)